CELATOR® PHARMACEUTICALS ANNOUNCES DATA AND SAFETY MONITORING BOARD RECOMMENDATION TO CONTINUE PHASE 3 STUDY OF CPX-351
December 1, 2014Celator Pharmaceuticals’ independent Data and Safety Monitoring Board has completed a safety review for their Phase 3 clinical study of CPX-351 to treat acute myeloid leukemia, and recommended that the study continue as planned without any modifications.
More »
The Scientist Names BioNano Genomics’ IrysChip V2 One of the Top 10 Innovations of 2014
December 1, 2014BioNano Genomics’ genome mapping technology, IrysChip V2, was named one of the Top 10 Innovations of 2014 by The Scientist. These innovations are laboratory and research products introduced in the past year that revolutionize the life sciences.
More »
Celator(R) Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting
November 24, 2014Celator Pharmaceuticals will present data on its lead product candidate, CPX-351, at the American Society of Hematology Annual Meeting and Exposition in San Francisco, December 6-9, and are hosting an investor reception December 6 at 7:30 PST.
More »